Trials / Active Not Recruiting
Active Not RecruitingNCT07413250
Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of IPIG-Registry Data
A Study to Assess Long-Term Safety of Danicopan Add-on Therapy in Participants With Paroxysmal Nocturnal Hemoglobinuria: Analysis of International PNH Interest Group (IPIG)-Registry Data
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a noninterventional registry-based cohort study utilizing data collected on danicopan-treated patients with paroxysmal nocturnal hemoglobinuria (PNH) through the International PNH Interest Group (IPIG) PNH registry. The primary objectives seek to characterize the long-term safety profile of danicopan as add-on therapy to ravulizumab/eculizumab in participants with PNH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Danicopan | Participants treated with danicopan as an add-on therapy. |
| DRUG | Soliris/Ultomiris | Participants treated with Soliris/Ultomiris monotherapy. |
Timeline
- Start date
- 2026-01-14
- Primary completion
- 2030-01-15
- Completion
- 2030-01-15
- First posted
- 2026-02-17
- Last updated
- 2026-02-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07413250. Inclusion in this directory is not an endorsement.